Clinical Trials Directory

Trials / Completed

CompletedNCT05129657

CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches

An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Three P10 Nicotine Pouches

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
RAI Services Company · Industry
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Accepted

Summary

This is a two-site, open-label, randomized, 5-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \[PD\]) and plasma nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of the study investigational products (IPs) by generally healthy smokers.

Detailed description

Cigarette smokers and smokers also using smokeless tobacco products (ST) will be recruited into this AL study to evaluate elements of AL of three nicotine pouches compared to combustible cigarettes (CC) and nicotine polacrilex gum. At least one-third of the study population will include smokers who also use ST. Potential subjects may complete a pre-screening telephone interview. Subjects will complete a Screening Visit to assess their eligibility within 45 days prior to check-in and enrollment. Starting on Day 1, subjects will check-in at the clinical site to complete procedures to confirm eligibility. Eligible subjects will be enrolled and confined for 6 days. Subjects will be randomized to one of 10 product use sequences (using a Williams Design) in which the subjects will evaluate one IP in each of five separate Test Sessions, such that each subject will evaluate five IPs, including three IPs, and both a high-AL comparator (subject's usual brand \[UB\] cigarette) and a low-AL comparator (a commercially available nicotine replacement therapy \[NRT\] nicotine gum). On Day 2 and continuing through Day 6, subjects will participate in Test Sessions that will last for approximately 4 hours. Each Test Session will include collection of both PD measures (subjective and physiological) and PK measures prior to, during, and following IP use. On the half day prior to each respective Test Session, a Product Acclimation Period will allow subjects ad libitum use of the randomized IP (at least two trial uses) for product familiarization prior to use in the next day's Test Session. Subjects can also use their UB cigarettes ad libitum, until the 12-hour tobacco abstinence begins prior to each Test Session, as long as the minimum use requirement for randomized IP is met.

Conditions

Interventions

TypeNameDescription
OTHERProduct AUsual Brand (UB) filtered, non-menthol or menthol cigarette
OTHERProduct BP1012914, A nicotine pouch product with 4 mg of nicotine
OTHERProduct CP1012915, A nicotine pouch product with 8 mg of nicotine
OTHERProduct DP1012919, A nicotine pouch product with 12 mg of nicotine
OTHERProduct NNicorette® White Ice Mint 4 mg nicotine gum

Timeline

Start date
2021-11-02
Primary completion
2022-06-24
Completion
2022-06-24
First posted
2021-11-22
Last updated
2024-04-30

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05129657. Inclusion in this directory is not an endorsement.

CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches (NCT05129657) · Clinical Trials Directory